Elevated C-reactive protein/albumin ratio in patients with methamphetamine use disorder

References

• Al-Rafiah, A., Magadmi, R., Al-Kaabi, A., & Alsomali, N. (2021). Parkinson’s disease-related biomarkers that may appear in amphetamine abusers. BioMed Research International, 2021, 1–8. doi:10.1155/2021/3081891.
   PubMed Web of Science ®Google Scholar
• Anglin, M. D., Burke, C., Perrochet, B., Stamper, E., & Dawud-Noursi, S. (2000). History of the methamphetamine problem. Journal of Psychoactive Drugs, 32(2), 137–141. doi:10.1080/02791072.2000.10400221.
   PubMed Web of Science ®Google Scholar
• Balcioglu, Y. H., & Kirlioglu, S. S. (2020). C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia. Psychiatry İnvestigation, 17(9), 902–910. doi:10.30773/pi.2020.0185.
   PubMed Web of Science ®Google Scholar
• Baykara, S., Şirin Berk, Ş., Kaya, Ş., & Ocak, D. (2022). Evaluation of complete blood cell count parameters and lymphocyte-related ratios in patients with Opioid Use Disorder. Journal of İmmunoassay & İmmunochemistry, 43(3), 259–270. doi:10.1080/15321819.2021.2001001.
   PubMedGoogle Scholar
• Bologa, R. M., Levine, D. M., Parker, T. S., Cheigh, J. S., Serur, D., Stenzel, K. H., & Rubin, A. L. (1998). Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. American Journal of Kidney Diseases, 32(1), 107–114. doi:10.1053/ajkd.1998.v32.pm9669431.
   PubMed Web of Science ®Google Scholar
• Chomchai, C., & Chomchai, S. (2015). Global patterns of methamphetamine use. Current Opinion in Psychiatry, 28(4), 269–274. doi:10.1097/YCO.0000000000000168.
   PubMed Web of Science ®Google Scholar
• Cıcek, E., Demırel, B., Cıcek, I. E., Kıraç, A. S., & Eren, I. (2018). Increased neutrophil-lymphocyte and platelet-lymphocyte ratios in male heroin addicts: a prospective controlled study. Clinical Psychopharmacology and Neuroscience, 16(2), 190–196. doi:10.9758/cpn.2018.16.2.190.
   PubMed Web of Science ®Google Scholar
• Copeland, W. E., Shanahan, L., Worthman, C., Angold, A., & Costello, E. J. (2012). Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis. Psychological Medicine, 42(12), 2641–2650. doi:10.1017/S0033291712000554.
   PubMed Web of Science ®Google Scholar
• Costello, E. J., Copeland, W. E., Shanahan, L., Worthman, C. M., & Angold, A. (2013). C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis. Drug and Alcohol Dependence, 133(2), 712–717. doi:10.1016/j.drugalcdep.2013.08.027.
   PubMed Web of Science ®Google Scholar
• Cruickshank, C. C., & Dyer, K. R. (2009). A review of the clinical pharmacology of methamphetamine. Addiction, 104(7), 1085–1099. doi:10.1111/j.1360-0443.2009.02564.x.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Sara, G., McKetin, R., Roxburgh, A., Dobbins, T., Farrell, M., Burns, L., & Hall, W. D. (2017). Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug and Alcohol Review, 36(2), 160–170. doi:10.1111/dar.12426.
   PubMed Web of Science ®Google Scholar
• Demir, B., Sahin, S. K., Ozsoy, F., Altindag, A., & Elboga, G, (2021a). Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in methamphetamine use disorder. Psychiatry and Clinical Psychopharmacology, 31(1), 34–39. doi: 10.5152/pcp.2021.20156.
   Web of Science ®Google Scholar
• Derlet, R. W., & Horowitz, B. Z. (1995). Cardiotoxic drugs. Emergency Medicine Clinics of North America, 13(4), 771–791. doi:10.1016/S0733-8627(20)30588-5.
   PubMedGoogle Scholar
• Duran-Güell, M., Flores-Costa, R., Casulleras, M., López-Vicario, C., Titos, E., Díaz, A., Alcaraz-Quiles, J., Horrillo, R., Costa, M., Fernández, J., Arroyo, V., & Clària, J. (2021). Albumin protects the liver from tumor necrosis factor α-induced immunopathology. FASEB Journal, 35(2), e21365. doi:10.1096/fj.202001615RRR.
   PubMed Web of Science ®Google Scholar
• Edition, F. (2013). Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc, 21(21), 591–643.
   Google Scholar
• Ekici, B., & Ozbay, S. (2013). Iranian methamphetamine and Turkey: an emerging transnational threat. Trends in Organized Crime, 16(3), 286–305. doi:10.1007/s12117-013-9204-6.
   Google Scholar
• Foulds, J. A., Boden, J. M., McKetin, R., & Newton-Howes, G. (2020). Methamphetamine use and violence: findings from a longitudinal birth cohort. Drug and Alcohol Dependence, 207, 107826. doi:10.1016/j.drugalcdep.2019.107826.
   PubMed Web of Science ®Google Scholar
• Gong, C., Wei, D., Wang, Y., Ma, J., Yuan, C., Zhang, W., Yu, G., & Zhao, Y. (2016). A meta-analysis of C-reactive protein in patients with Alzheimer’s disease. American Journal of Alzheimer’s Disease and Other Dementias, 31(3), 194–200. doi: 10.1177/1533317515602087.
   PubMed Web of Science ®Google Scholar
• Gulhar, R., Ashraf, M. A., & Jialal, I. (2018). Physiology, acute phase reactants.
   Google Scholar
• Guzel, D., Yazici, A. B., Yazici, E., & Erol, A. (2017). Alterations of the hematologic cells in synthetic cannabinoid users. Journal of Clinical Laboratory Analysis, 31(6), e22131. doi:10.1002/jcla.22131.
   PubMed Web of Science ®Google Scholar
• Hang, J., Xue, P., Yang, H., Li, S., Chen, D., Zhu, L., Huang, W., Ren, S., Zhu, Y., & Wang, L. (2017). Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Scientific Reports, 7(1), 1–9. doi: 10.1038/s41598-017-03153-6.
   PubMedGoogle Scholar
• Harnett, J. T., Dargan, P. I., Dines, A. M., Archer, J. R., Greene, S. L., Hunter, L. J., & Wood, D. M. (2022). Increasing emergency department attendances in central London with methamphetamine toxicity and associated harms. Emergency Medicine Journal, 39(6), 463–466. doi:10.1136/emermed-2020-209550.
   PubMed Web of Science ®Google Scholar
• Hebert, M. A., & O’Callaghan, J. P. (2000). Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Annals of the New York Academy of Sciences, 914(1), 238–262. doi:10.1111/j.1749-6632.2000.tb05200.x.
   PubMedGoogle Scholar
• Homer, B. D., Solomon, T. M., Moeller, R. W., Mascia, A., DeRaleau, L., & Halkitis, P. N. (2008). Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychological Bulletin, 134(2), 301–310. doi:10.1037/0033-2909.134.2.301.
   PubMed Web of Science ®Google Scholar
• Hu, Z., Wang, J., Xue, Y., Zhang, Q., Xu, Q., Ji, K., & Yin, R. (2022). The Neutrophil-to-Albumin Ratio as a New Predictor of All-Cause Mortality in Patients with Heart Failure. Journal of İnflammation Research, 15, 701–713. doi:10.2147/JIR.S349996.
   PubMed Web of Science ®Google Scholar
• Jones, C. M., Olsen, E. O., O’Donnell, J., & Mustaquim, D. (2020). Resurgent methamphetamine use at treatment admission in the United States, 2008–2017. American Journal of Public Health, 110(4), 509–516. doi:10.2105/AJPH.2019.305527.
   PubMed Web of Science ®Google Scholar
• Kany, S., Vollrath, J. T., & Relja, B. (2019). Cytokines in inflammatory disease. International Journal of Molecular Sciences, 20(23), 6008. doi: 10.3390/ijms20236008.
   PubMed Web of Science ®Google Scholar
• Karakukcu, C., Ciraci, M. Z., Kocer, D., Zararsiz, G. E., Reyhancan, M., & Altintop, I. (2018). Regional drug abuse prevalence depending on laboratory based urine illicit drug screening results/Laboratuvar verilerine dayali idrarda yasa disi madde analiz sonuclarina gore bolgesel madde kullanim yayginliginin belirlenmesi. Anatolian Journal of Psychiatry, 19(2), 169–177. doi:10.5455/apd.264474.
   Google Scholar
• Kevil, C. G., Goeders, N. E., Woolard, M. D., Bhuiyan, M. S., Dominic, P., Kolluru, G. K., Arnold, C. L., Traylor, J. G., & Orr, A. W. (2019). Methamphetamine use and cardiovascular disease: in search of answers. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(9), 1739–1746. doi:10.1161/ATVBAHA.119.312461.
   PubMed Web of Science ®Google Scholar
• Kim, B., Yun, J., & Park, B. (2020). Methamphetamine-induced neuronal damage: neurotoxicity and neuroinflammation. Biomolecules & Therapeutics, 28(5), 381–388. doi:10.4062/biomolther.2020.044.
   PubMed Web of Science ®Google Scholar
• Kish, S. J. (2008). Pharmacologic mechanisms of crystal meth. CMAJ, 178(13), 1679–1682. doi: 10.1503/cmaj.071675.
   PubMed Web of Science ®Google Scholar
• Lee, H. H., Sudhakara, P., Desai, S., Miranda, K., & Martinez, L. R. (2021). Understanding the basis of METH mouth using a rodent model of methamphetamine ınjection, sugar consumption, and streptococcus mutans ınfection. mBio, 12(2), e03534–03520. doi: 10.1128/mBio.03534-20.
   PubMed Web of Science ®Google Scholar
• Liśkiewicz, A., Przybyła, M., Park, M., Liśkiewicz, D., Nowacka-Chmielewska, M., Małecki, A., Barski, J., Lewin-Kowalik, J., & Toborek, M. (2019). Methamphetamine-associated cognitive decline is attenuated by neutralizing IL-1 signaling. Brain, Behavior, and İmmunity, 80, 247–254. doi:10.1016/j.bbi.2019.03.016.
   PubMed Web of Science ®Google Scholar
• Liu, X., Silverstein, P. S., Singh, V., Shah, A., Qureshi, N., & Kumar, A. (2012). Methamphetamine increases LPS-mediated expression of IL-8, TNF-α and IL-1β in human macrophages through common signaling pathways. PloS One, 7(3), e33822. doi:10.1371/journal.pone.0033822.
   PubMed Web of Science ®Google Scholar
• Loftis, J. M., Choi, D., Hoffman, W., & Huckans, M. S. (2011). Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotoxicity Research, 20(1), 59–68. doi:10.1007/s12640-010-9223-x.
   PubMed Web of Science ®Google Scholar
• McKetin, R., Kelly, E., & McLaren, J. (2006). The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug and Alcohol Dependence, 85(3), 198–204. doi:10.1016/j.drugalcdep.2006.04.007.
   PubMed Web of Science ®Google Scholar
• Miller, B. J., Culpepper, N., & Rapaport, M. H. (2014). C-reactive protein levels in schizophrenia: a review and meta-analysis. Clinical Schizophrenia & Related Psychoses, 7(4), 223–230. doi:10.3371/CSRP.MICU.020813.
   PubMedGoogle Scholar
• Ngwa, D. N., Pathak, A., & Agrawal, A. (2022). IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Molecular İmmunology, 146, 50–56. doi:10.1016/j.molimm.2022.04.003.
   PubMed Web of Science ®Google Scholar
• Orsolini, L., Sarchione, F., Vellante, F., Fornaro, M., Matarazzo, I., Martinotti, G., Valchera, A., Di Nicola, M., Carano, A., Di Giannantonio, M., Perna, G., Olivieri, L., & De Berardis, D. (2018). Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Current Neuropharmacology, 16(5), 583–606. doi:10.2174/1570159X16666180119144538.
   PubMed Web of Science ®Google Scholar
• Orum, M. H., Kara, M. Z., Egilmez, O. B., & Kalenderoglu, A. (2018). Complete blood count alterations due to the opioid use: what about the lymphocyte-related ratios, especially in monocyte to lymphocyte ratio and platelet to lymphocyte ratio? Journal of İmmunoassay & İmmunochemistry, 39(4), 365–376. doi:10.1080/15321819.2018.1460272.
   PubMedGoogle Scholar
• Ozkan, N., Sonmez, M., Durmus, P. T., Gorgulu, Y., Cınar, R. K., & Vardar, M. (2017). Elevated neutrophil lymphocyte ratio in patients with substance use disorders. European Psychiatry, 41(S1), S872–S873. doi:10.1016/j.eurpsy.2017.01.1754.
   Google Scholar
• Örüm, M. H. (2021). Characteristics of Cases Hospitalized in a Mental Health and Diseases Hospital within the scope of Article 432 of the Turkish Civil Code. Bağımlılık Dergisi, 22(3), 226–235. doi:10.51982/bagimli.887881.
   Google Scholar
• Park, J., Chung, K., Song, J., Kim, S., Kim, E., Jung, J., Kang, Y., Park, M., Kim, Y., Chang, J., & Leem, A. (2018). The C-reactive protein/albumin ratio as a predictor of mortality in critically ill patients. Journal of Clinical Medicine, 7(10), 333. doi:10.3390/jcm7100333.
   PubMed Web of Science ®Google Scholar
• Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: a critical update. The Journal of Clinical İnvestigation, 111(12), 1805–1812. doi:10.1172/JCI200318921.
   PubMed Web of Science ®Google Scholar
• Ranzani, O. T., Zampieri, F. G., Forte, D. N., Azevedo, L. C. P., & Park, M. (2013). C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PloS One, 8(3), e59321. doi:10.1371/journal.pone.0059321.
   PubMed Web of Science ®Google Scholar
• Salamanca, S. A., Sorrentino, E. E., Nosanchuk, J. D., & Martinez, L. R. (2014). Impact of methamphetamine on infection and immunity. Frontiers in Neuroscience, 8, 445. doi: 10.3389/fnins.2014.00445.
   PubMed Web of Science ®Google Scholar
• Sheinenzon, A., Shehadeh, M., Michelis, R., Shaoul, E., & Ronen, O. (2021). Serum albumin levels and inflammation. International Journal of Biological Macromolecules, 184, 857–862. doi: 10.1016/j.ijbiomac.2021.06.140.
   PubMed Web of Science ®Google Scholar
• Sun, P., Chen, C., Xia, Y., Bi, X., Liu, P., Zhang, F., Yang, H., An, X., Jiang, W., & Wang, F. (2017). The ratio of C-reactive protein/albumin is a novel inflammatory predictor of overall survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma. Disease Markers, 2017, 1–9. doi:10.1155/2017/6570808.
   Web of Science ®Google Scholar
• Tingle, S. J., Severs, G. R., Goodfellow, M., Moir, J. A., & White, S. A. (2018). NARCA: a novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. Journal of Surgical Oncology, 118(4), 680–686. doi:10.1002/jso.25209.
   PubMed Web of Science ®Google Scholar
• Tocharus, J., Khonthun, C., Chongthammakun, S., & Govitrapong, P. (2010). Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. Journal of Pineal Research, 48(4), 347–352. doi:10.1111/j.1600-079X.2010.00761.x.
   PubMed Web of Science ®Google Scholar
• Towfighi, A., Cheng, E. M., Ayala-Rivera, M., McCreath, H., Sanossian, N., Dutta, T., Mehta, B., Bryg, R., Rao, N., Song, S., Razmara, A., Ramirez, M., Sivers-Teixeira, T., Tran, J., Mojarro-Huang, E., Montoya, A., Corrales, M., Martinez, B., Willis, P., … Vickrey, B. G. (2017). Randomized controlled trial of a coordinated care intervention to improve risk factor control after stroke or transient ischemic attack in the safety net: secondary stroke prevention by Uniting Community and Chronic care model teams Early to End Disparities (SUCCEED). BMC Neurology, 17(1), 1–20. doi:10.1186/s12883-017-0792-7.
   PubMedGoogle Scholar
• Turowski, P., & Kenny, B.-A. (2015). The blood-brain barrier and methamphetamine: open sesame? Frontiers in Neuroscience, 9, 156. doi:10.3389/fnins.2015.00156.
   PubMed Web of Science ®Google Scholar
• Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013). CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. Journal of Affective Disorders, 150(3), 736–744. doi:10.1016/j.jad.2013.06.004.
   PubMed Web of Science ®Google Scholar
• Varim, C., Celik, F., Sunu, C., Öztop, K., Aydın, A., Yaylaci, S., Karacaer, C., Gülbagcı, B., Demirci, A., & Kaya, T. (2022). The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer. European Review for Medical and Pharmacological Sciences, 26(8), 2900–2905.
   PubMed Web of Science ®Google Scholar
• Wang, J., Lu, C., Zheng, L., & Zhang, J. (2021). Peripheral ınflammatory biomarkers of methamphetamine withdrawal patients based on the neuro-ınflammation hypothesis: the possible ımprovement effect of exercise. Frontiers in Psychiatry, 12 doi:10.3389/fpsyt.2021.795073.
   Web of Science ®Google Scholar
• Wysokiński, A., Margulska, A., Strzelecki, D., & Kłoszewska, I. (2015). Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nordic Journal of Psychiatry, 69(5), 346–353. doi:10.3109/08039488.2014.984755.
   PubMed Web of Science ®Google Scholar
• Yamamoto, B. K., & Zhu, W. (1998). The effects of methamphetamine on the production of free radicals and oxidative stress. The Journal of Pharmacology and Experimental Therapeutics, 287(1), 107–114.
   PubMed Web of Science ®Google Scholar
• Yang, C., Fu, X., Hao, W., Xiang, X., Liu, T., Yang, B. Z., & Zhang, X. (2021). Gut dysbiosis associated with the rats’ responses in methamphetamine-induced conditioned place preference. Addiction Biology, 26(4), e12975. doi:10.1111/adb.12975.
   PubMed Web of Science ®Google Scholar
• Yang, X., Wang, Y., Li, Q., Zhong, Y., Chen, L., Du, Y., He, J., Liao, L., Xiong, K., Yi, C.-X., & Yan, J. (2018). The main molecular mechanisms underlying methamphetamine-induced neurotoxicity and implications for pharmacological treatment. Frontiers in Molecular Neuroscience, 11, 186. doi:10.3389/fnmol.2018.00186.
   PubMed Web of Science ®Google Scholar
• Yazar, H. O., Yazar, T., Özdemir, S., & Arici, Y. K. (2019). Serum C-reactive protein/albumin ratio and restless legs syndrome. Sleep Medicine, 58, 61–65. doi:10.1016/j.sleep.2019.02.022.
   PubMed Web of Science ®Google Scholar
• Yazar, T., & Yazar, H. O. (2019). Evaluation of C-reactive protein/albumin ratio according to stage in patients with ıdiopathic parkinson disease/ıdiyopatik parkinson hastaligi tanisi olan hastalarda evrelere gore c-reaktif protein/albumin oranlarinin degerlendirilmesi. Turkish Journal Of Neurology, 25(3), 123–128. doi:10.4274/tnd.galenos.2019.13334.
   Web of Science ®Google Scholar
• Zhang, C., Luo, T., Liu, L., Dong, H., & Hao, W. (2018). Prevalence rates of personality disorder and its association with methamphetamine dependence in compulsory treatment facilities in China. Frontiers in Psychiatry, 9, 698. doi:10.3389/fpsyt.2018.00698.
   PubMed Web of Science ®Google Scholar